AnaptysBio’s Imsidolimab Meets Yet Another Failure
The company is discontinuing the drug’s development in hidradenitis suppurativa after a Phase II flop, leaving GPP as the only viable indication, for which it is planning to out-license the drug.
The company is discontinuing the drug’s development in hidradenitis suppurativa after a Phase II flop, leaving GPP as the only viable indication, for which it is planning to out-license the drug.